Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

Duke University: Clinical Trials & FDA Approval Profile

Duke University (Durham, NC) sponsors 80 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 28 active protocols (18 recruiting now), 33 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)23.8%
Median Closed Enrollment vs National (145 pts)32 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Duke University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)80
Active Pipeline (Recruiting Now)28 (18)
Completed vs Stopped Early33 / 19 (23.8%)
Median Closed Actual Enrollment32 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Duke University
Hospital Research SiteLocationShared Protocols
Duke University Medical CenterDurham, NC53
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CA4
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MD4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Duke University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07232069PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosisPhase IIIRECRUITING
NCT06404086RECOVER-SLEEP: Platform ProtocolPhase IICOMPLETED
NCT03841357Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)Phase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Duke University Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI